Restoring immune tolerance in pemphigus vulgaris

Area of Science:

• Immunology
• Dermatology
• Autoimmune Diseases

Background:

• Intravenous immunoglobulin (IVIg) is a polyclonal IgG preparation used for autoimmune blistering diseases like pemphigus vulgaris (PV).
• Despite its efficacy, IVIg's precise mechanisms of action in treating PV remain incompletely understood.
• Existing research has explored some of IVIg's anti-inflammatory and immunomodulatory effects.

Purpose of the Study:

• To evaluate the long-term efficacy and safety of IVIg monotherapy in patients with pemphigus vulgaris.
• To investigate the potential for sustained immune balance or regulation restoration in PV patients treated with IVIg.
• To establish a human model for studying autoimmunity pathophysiology and immune tolerance mechanisms.

Main Methods:

• A twenty-year follow-up study of 21 patients with confirmed PV.
• Patients were treated with IVIg monotherapy following a published protocol.
• Clinical, serological, and immunopathological parameters were monitored throughout the follow-up period.

Main Results:

• IVIg monotherapy resulted in sustained long-term clinical, serological, and immunopathological remission in PV patients.
• Twelve patients (57%) experienced no relapse over 20 years, indicating potential immune restoration.
• Six patients (29%) relapsed due to triggers like stress or infection, but recovered promptly upon reinstituting IVIg. No severe adverse effects were reported.

Conclusions:

• IVIg monotherapy can induce long-term sustained remission in pemphigus vulgaris, potentially by restoring immune balance.
• The study highlights IVIg's role in modulating immune responses and facilitating immune tolerance.
• This research offers a valuable human model for understanding autoimmune disease pathophysiology and developing new therapeutic strategies.